Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV

Background. Tenofovir disoproxil fumarate (TDF) or its prodrug tenofovir alafenamide fumarate (TAF) are currently being recommended in treatment of HIV infection. Distinct pharmacological properties of these two forms of a this drug make TAF treatment less nephrotoxic and lead to better impact on b...

詳細記述

書誌詳細

主要な著者:	Michał Łomiak, Zofia Gajek, Jan Stępnicki, Agnieszka Lembas, Tomasz Mikuła, Alicja Wiercińska-Drapało
フォーマット:	Artigo
言語:	Inglês
出版事項:	Poznan University of Medical Sciences 2023-09-01
シリーズ:	Journal of Medical Science
主題:	antiretroviral therapy tenofovir disoproxil fumarate tenofovir alafenamide lipids cholesterol low-density lipoproteins
オンライン･アクセス:	https://jms.ump.edu.pl/index.php/JMS/article/view/808
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!